Stockscreener 앱 받기
0.0913
0.00%
0.0007
전일 마감가:
$0.092
열려 있는:
$0.0919
하루 거래량:
4.53M
Relative Volume:
0.95
시가총액:
$8.78M
수익:
-
순이익/손실:
$-37.28M
주가수익비율:
-0.1323
EPS:
-0.69
순현금흐름:
$-32.24M
1주 성능:
-15.60%
1개월 성능:
-81.93%
6개월 성능:
-87.90%
1년 성능:
-93.57%
1일 변동 폭
$0.0905
$0.0965
1주일 범위
$0.089
$0.1033
52주 변동 폭
$0.079
$2.57
Eyenovia Inc Stock (EYEN) Company Profile
명칭
Eyenovia Inc
전화
813-766-9539
주소
295 MADISON AVENUE,, NEW YORK, NY
EYEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
0.0912 | 8.78M | 0 | -37.28M | -32.24M | -0.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.58 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.65 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
609.37 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.46 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.60 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-03-01 | 개시 | Northland Capital | Outperform |
| 2020-02-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
Eyenovia Inc 주식(EYEN)의 최신 뉴스
These Numbers Show Just How Powerful Eyenovia Inc (NASDAQ: EYEN) Stock Is - Stocks Register
Eyenovia’s Direct Offering to Support Strategic Initiatives - TipRanks
SEC Form 424B5 filed by Eyenovia Inc. - Quantisnow
Eyenovia secures $1.3 million in direct offering By Investing.com - Investing.com South Africa
Eyenovia defers loan payments, issues equity to lenders - Investing.com
Eyenovia defers loan payments, issues equity to lenders By Investing.com - Investing.com Canada
Eyenovia Slumps On Pricing Of Registered Direct Offering - Nasdaq
Eyenovia Restructures Finances and Leadership Team - TipRanks
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering - The Manila Times
Eyenovia secures $1.3 million in direct offering - Investing.com
Eyenovia Raises $1.3M in Direct Offering at $0.1076 Per Share with Warrants | EYEN Stock News - StockTitan
Eyenovia taking additional actions to reduce personnel-related costs by over 70% - Yahoo Finance
Eyenovia secures debt payment deferral from Avenue Capital By Investing.com - Investing.com Nigeria
Eyenovia Continues to Evaluate Broad Range of Strategic Alternatives to Maximize Stakeholder Value - Marketscreener.com
Eyenovia secures debt payment deferral from Avenue Capital - Investing.com
Eyenovia Provides Update on Restructuring Efforts - The Manila Times
Eyenovia Provides Update on Restructuring Efforts - GlobeNewswire Inc.
Eyenovia reports low cash reserves; in talks for debt restructuring By Investing.com - Investing.com South Africa
Eyenovia reports low cash reserves; in talks for debt restructuring - Investing.com
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study - MSN
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
William Blair Reaffirms “Market Perform” Rating for Eyenovia (NASDAQ:EYEN) - Defense World
Eyenovia (NASDAQ:EYEN) Earns Hold Rating from Brookline Capital Management - Defense World
Eyenovia stock plummets following Phase III myopia trial failure - Clinical Trials Arena
Black Friday for Eyenovia as shares fall 70% - The Pharma Letter
Eyenovia stock downgraded to Neutral, price target set on challenges By Investing.com - Investing.com UK
Eyenovia halts myopia study after missing primary endpoint - Investing.com India
Eyenovia, Inc. Provides Update on Phase 3 CHAPERONE Study - Marketscreener.com
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints - MarketWatch
Eyenovia to end eye drug study, cut 50% of its workforce - Reuters
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - AOL
Eyenovia Shares Plumb New Depths After Study Failure - MarketWatch
Eyenovia Shares Plummet 70% After It Drops Lead Program - BioSpace
Eyenovia plunges as late-stage trial for myopia treatment fails - MSN
Eyenovia stock plunges after trial setback (EYEN:NASDAQ) - Seeking Alpha
Eyenovia discontinues late-stage eye drug study, shares fall - XM
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Eyenovia Inc - GuruFocus.com
Eyenovia Mulls Options After Phase 3 Study Failure - MarketWatch
Eyenovia Provides Update on Phase 3 CHAPERONE Study - The Manila Times
Eyenovia Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Eyenovia's Phase 3 Myopia Drug Trial Fails Primary Endpoint, Company Weighs Options | EYEN Stock News - StockTitan
Eyenovia, Inc. (NASDAQ:EYEN) Q3 2024 Earnings Call Transcript - Insider Monkey
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Eyenovia Inc (EYEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Eyenovia Inc 주식 (EYEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
| Grant Stuart M. | 10% Owner |
Mar 28 '24 |
Buy |
0.98 |
100,000 |
98,000 |
5,430,715 |
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
| Rowe Michael M | Chief Executive Officer |
Dec 04 '23 |
Buy |
1.36 |
4,890 |
6,650 |
32,927 |
0.43%
0.52%
자본화:
|
볼륨(24시간):